Nektar Therapeutics (NKTR) Restructuring Costs (2022 - 2026)

Nektar Therapeutics' Restructuring Costs history runs 5 years deep, the most recent figure standing at $796000.0 for Q1 2026.

• On a quarterly basis, Restructuring Costs rose 371.01% year-over-year to $796000.0 in Q1 2026; TTM through Mar 2026 was $10.0 million, a 33.01% decrease from a year earlier, with the FY2025 full-year figure at $9.3 million, down 40.45% from the prior year.
• Restructuring Costs declined to $796000.0 in Q1 2026 per NKTR's latest filing, from $8.6 million in the prior quarter.
• Across five years, Restructuring Costs topped out at $106.0 million in Q2 2022 and bottomed at -$41.2 million in Q4 2023.
• The 5-year median for Restructuring Costs is $1.4 million (2023), against an average of $7.3 million.
• Across the five-year window, Restructuring Costs plunged 455.85% in 2023 and surged 880.01% in 2024, its largest moves.
• Year by year, Restructuring Costs stood at $11.6 million in 2022, then plunged by 455.85% to -$41.2 million in 2023, then soared by 103.3% to $1.4 million in 2024, then surged by 530.51% to $8.6 million in 2025, then sank by 90.72% to $796000.0 in 2026.
• Per Business Quant, the three latest NKTR Restructuring Costs figures stand at $796000.0 (Q1 2026), $8.6 million (Q4 2025), and $140000.0 (Q3 2025).